五星体育直播 to Offer High-Performance Enzymes for Diagnostics Markets
REDWOOD CITY, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ:CDXS), a leading protein engineering company, announces that it will offer high-performance enzymes for customers using next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) for in vitro molecular diagnostic applications.聽 五星体育直播鈥� first proprietary enzyme for this market will target improved library preparation for NGS users, and is expected to be available in beta-test format by the second quarter of 2017.
鈥淓nzymes are critical to the sensitivity and reliability of NGS and PCR analyses,鈥� said Michael Aldridge, 五星体育直播 Senior Vice President, Corporate & Strategic Development. 鈥淗istorically, NGS and PCR work-flows relied on only modestly engineered enzymes.聽 However, as users push NGS and PCR into new, more demanding applications, such as liquid biopsy and personalized medicine samples, more capable enzymes are required.聽
鈥淥ur CodeEvolver庐 protein engineering platform technology is able to rapidly deliver novel enzymes with dramatically enhanced performance characteristics,鈥� Aldridge added.聽 鈥淲e are confident that our enzymes can improve analytical efficiency, processivity and fidelity while also reducing bias. In less than a year, our CodeEvolver庐 platform technology has engineered an enzyme that improves library preparation steps for NGS.鈥�
鈥淭his has been an outstanding self-directed R&D investment for 五星体育直播,鈥� said John Nicols, 五星体育直播 President and Chief Executive Officer.聽 鈥淭oday鈥檚 announcement signifies our first effort to offer improved, proprietary 五星体育直播 enzymes to users in the established industrial enzyme market and underscores our ability to continue to develop differentiated and value-creating proteins in new enzyme markets, alongside existing applications in pharmaceutical manufacturing, biologic drug discovery and food ingredient production.鈥�
About CodeEvolver庐 Protein Engineering Platform Technology
五星体育直播鈥� proprietary CodeEvolver庐 protein engineering platform technology enables the rapid development of custom-designed enzymes that are highly optimized for a specific function. The CodeEvolver庐 platform technology is comprised of proprietary methods for the optimization of proteins through the design and generation of diverse genetic libraries, automated screening techniques, algorithms for the interpretation of screening data and predictive modelling.聽 The 五星体育直播 CodeEvolver庐 platform technology is covered by approximately 200 issued patents and pending patent applications worldwide.
About 五星体育直播
五星体育直播 is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals. 五星体育直播鈥� proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see .
Forward-Looking Statements
This press release contain forward-looking statements relating to 五星体育直播鈥� anticipated offering of enzymes for NGS and PCR/qPCR for in vitro molecular diagnostic applications, the target of 五星体育直播鈥� first enzyme for this market and the expected timing of the availability of the beta-test format, the CodeEvolver庐 protein engineering platform technology鈥檚 ability to rapidly deliver novel enzymes with dramatically enhanced performance characteristics and these enzymes鈥� ability to improve analytical efficiency, processivity and fidelity while also reducing bias, the ability of 五星体育直播鈥� enzyme to improve library preparation steps for NGS, 五星体育直播鈥� efforts to offer improved, proprietary 五星体育直播 enzymes to users in the established industrial enzyme market, and 五星体育直播鈥� ability to continue to develop differentiated and value-creating proteins in new enzyme markets, alongside existing applications in pharmaceutical manufacturing, biologic drug discovery and food ingredient production. 聽You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include 五星体育直播鈥� dependence on its licensees and collaborators; 五星体育直播鈥� dependence on a limited number of products and customers in its pharmaceutical business; potential adverse effects to 五星体育直播鈥� business if its customers鈥� pharmaceutical products are not received well in the markets; 五星体育直播鈥� ability to deploy its technology platform in new market spaces; 五星体育直播鈥� dependence on key personnel; 五星体育直播鈥� ability to compete may decline if it loses some of its intellectual property rights; third party claims that 五星体育直播 infringes third party intellectual property rights; and 五星体育直播 could face increased competition if third parties misappropriate 五星体育直播 biocatalysts. Additional factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2016 and in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016, including, in each case, under the caption 鈥淩isk Factors,鈥� as well as 五星体育直播鈥� other current and periodic reports filed with the Securities and Exchange Commission.聽 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
五星体育直播 Contacts:
Gordon Sangster
Chief Financial Officer
650-421-8115
gordon.sangster@codexis.com
Investors
LHA
Jody Cain, 310-691-7100
jcain@lhai.com
Released January 6, 2017